STOCK TITAN

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags

Illumina (NASDAQ: ILMN) and Nashville Biosciences announced that Alnylam Pharmaceuticals (NASDAQ: ALNY) has joined the Alliance for Genomic Discovery (AGD) as its ninth member. Alnylam, specializing in RNA interference therapeutics, will leverage the AGD's clinical genomic database to accelerate drug target discovery.

The partnership will contribute to expanding the database by adding 31,250 new whole-genomes to the existing 250,000 whole-genome cohort. The AGD dataset, completed in March 2025, combines diverse genomic data with longitudinal clinical phenotyping, utilizing Illumina's DRAGEN™ and Connected Analytics platforms for rapid analysis and insights generation.

Alnylam joins existing members including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk in this collaborative effort to advance therapeutic discoveries, particularly in autoimmune and neurodegenerative diseases.

Illumina (NASDAQ: ILMN) e Nashville Biosciences hanno annunciato che Alnylam Pharmaceuticals (NASDAQ: ALNY) si è unita all'Alliance for Genomic Discovery (AGD) come nono membro. Alnylam, specializzata in terapie basate sull'interferenza dell'RNA, utilizzerà il database genomico clinico dell'AGD per accelerare la scoperta di bersagli farmacologici.

La partnership contribuirà ad espandere il database aggiungendo 31.250 nuovi genomi completi all’attuale coorte di 250.000 genomi completi. Il set di dati AGD, portato a termine a marzo 2025, combina dati genomici diversi con fenotipizzazione clinica longitudinale, impiegando le piattaforme DRAGEN™ e Connected Analytics di Illumina per un’analisi rapida e l’ottenimento di insight.

Alnylam si unisce agli attuali membri tra cui AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck e Novo Nordisk in questo sforzo collaborativo per avanzare le scoperte terapeutiche, in particolare nelle malattie autoimmuni e neurodegenerative.

Illumina (NASDAQ: ILMN) y Nashville Biosciences anunciaron que Alnylam Pharmaceuticals (NASDAQ: ALNY) se ha unido a la Alliance for Genomic Discovery (AGD) como su noveno miembro. Alnylam, que se especializa en terapias de interferencia de ARN, aprovechará la base de datos genómica clínica de la AGD para acelerar el descubrimiento de blancos farmacológicos.

La asociación contribuirá a ampliar la base de datos añadiendo 31,250 nuevos genomas completos a la ya existente cohorte de 250,000 genomas completos. El conjunto de datos de la AGD, completado en marzo de 2025, combina datos genómicos diversos con fenotipado clínico longitudinal, utilizando las plataformas DRAGEN™ y Connected Analytics de Illumina para un análisis rápido y la generación de ideas.

Alnylam se une a los miembros existentes que incluyen AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck y Novo Nordisk en este esfuerzo colaborativo para avanzar en descubrimientos terapéuticos, especialmente en enfermedades autoinmunes y neurodegenerativas.

Illumina (NASDAQ: ILMN)과 내슈빌 바이오사이언스는 Alnylam Pharmaceuticals (NASDAQ: ALNY)가 제9의 멤버로 AGD(Alliance for Genomic Discovery)에 합류했다고 발표했습니다. RNA 간섭 치료제를 전문으로 하는 알니람은 AGD의 임상 유전체 데이터베이스를 활용해 약물 표적 발견을 가속화할 것입니다.

파트너십은 기존의 250,000명의 전체 게놈 코호트31,250개의 신규 전체 게놈을 추가해 데이터베이스를 확장하는 데 기여할 것입니다. 2025년 3월에 완성된 AGD 데이터 세트는 다양한 유전체 데이터와 종단적 임상 표현형을 결합하고, Illumina의 DRAGEN™ 및 Connected Analytics 플랫폼을 활용해 신속한 분석과 인사이트 생성을 제공합니다.

알니람은 이 협력의 일환으로 AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novo Nordisk 등 기존 멤버와 함께 자가면역 및 신경퇴행성 질환 분야의 치료 발견을 촉진하는 노력을 이어갑니다.

Illumina (NASDAQ: ILMN) et Nashville Biosciences ont annoncé que Alnylam Pharmaceuticals (NASDAQ: ALNY) a rejoint l’Alliance for Genomic Discovery (AGD) en tant que neuvième membre. Spécialisée dans les thérapies par interruption de l’ARN, Alnylam utilisera la base de données génomiques cliniques de l’AGD pour accélérer la découverte de cibles médicamenteuses.

Le partenariat contribuera à l’expansion de la base de données en ajoutant 31 250 nouveaux génomes complets à la cohorte existante de 250 000 génomes complets. Le jeu de données AGD, achevé en mars 2025, combine des données génomiques variées avec un phénotage clinique longitudinal, en utilisant les plateformes DRAGEN™ et Connected Analytics d’Illumina pour une analyse rapide et la génération d’insights.

Alnylam rejoint les membres actuels tels qu’AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck et Novo Nordisk dans cet effort collaboratif pour faire progresser les découvertes thérapeutiques, en particulier dans les maladies auto-immunes et neurodégénératives.

Illumina (NASDAQ: ILMN) und Nashville Biosciences gaben bekannt, dass Alnylam Pharmaceuticals (NASDAQ: ALNY) als neuntes Mitglied der Alliance for Genomic Discovery (AGD) beigetreten ist. Alnylam, spezialisiert auf Therapeutika auf RNA-Interferenz, wird die klinische genomische Datenbank der AGD nutzen, um die Entdeckung von Zielstrukturen für Medikamente zu beschleunigen.

Die Partnerschaft wird dazu beitragen, die Datenbank zu erweitern, indem 31.250 neue vollständige Genome zur bestehenden Kohorte von 250.000 vollständigen Genomen hinzugefügt werden. Der AGD-Datensatz, der im März 2025 abgeschlossen wurde, kombiniert vielfältige genomische Daten mit longitudinalen klinischen Phänotypen und nutzt Illuminas DRAGEN™- und Connected Analytics-Plattformen für eine schnelle Analyse und Erkenntnisgewinnung.

Alnylam schließt sich den bestehenden Mitgliedern wie AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck und Novo Nordisk an, um in dieser gemeinschaftlichen Anstrengung Entdeckungen im therapeutischen Bereich voranzutreiben, insbesondere bei Autoimmun- und neurodegenerativen Erkrankungen.

Illumina (NASDAQ: ILMN) و أعلنوا أن Alnylam Pharmaceuticals (NASDAQ: ALNY) انضمت إلى التحالف من أجل الاكتشاف الجيني (AGD) كعضوها التاسع. تتخصص Alnylam في العلاجات المستندة إلى RNA interference، وستستفيد من قاعدة البيانات الجينية السريرية لـ AGD لتسريع اكتشاف أهداف الدواء.

سيسهم الشراكة في توسيع قاعدة البيانات من خلال إضافة 31,250 جينوماً كاملاً جديداً إلى حتى الآن 250,000 جينوم كامل في مجموعة البيانات. ومجموعة بيانات AGD المكتملة في مارس 2025 تجمع بين بيانات جينية متنوعة و phenotype سريري طولي، وتستخدم منصات Illumina DRAGEN™ وConnected Analytics للتحليل السريع واستخلاص الرؤى.

ينضم Alnylam إلى الأعضاء الحاليين بمن فيهم AbbVie وAmgen وAstraZeneca وBayer وBristol Myers Squibb وGSK وMerck وNovo Nordisk في هذا الجهد التعاوني لتقديم اكتشافات علاجية، خاصة في أمراض المناعة الذاتية والأمراض العصبية-التدهور.

Illumina(NASDAQ: ILMN)Nashville Biosciences 宣布,Alnylam Pharmaceuticals(NASDAQ: ALNY) 已加入基因组发现联盟(AGD),成为第九位成员。Alnylam 专注于RNA干扰治疗,将利用AGD的临床基因组数据库来加速药物靶点发现。

该伙伴关系将通过新增 31,250个全基因组,在现有的 25万全基因组队列 上扩展数据库。AGD 数据集于2025年3月完成,结合了多样的基因组数据与纵向临床表型,利用 Illumina 的 DRAGEN™ 与 Connected Analytics 平台实现快速分析与洞察生成。

Alnylam 将与现有成员包括 AbbVie、Amgen、AstraZeneca、Bayer、Bristol Myers Squibb、GSK、Merck 和 Novo Nordisk 等一起,在这一协作努力中推进治疗发现,特别是在自身免疫和神经退行性疾病领域。

Positive
  • Expansion of AGD dataset with additional 31,250 whole-genomes
  • Novel therapeutic targets identified in autoimmune and neurodegenerative diseases
  • Partnership with major pharmaceutical company strengthens research capabilities
  • Enhanced variant calling accuracy across diverse populations through DRAGEN technology
Negative
  • None.

Insights

Alnylam joining Illumina's AGD strengthens the alliance's dataset, potentially accelerating therapeutic discoveries and expanding Illumina's market leadership.

This announcement marks a strategic expansion of Illumina's Alliance for Genomic Discovery with the addition of Alnylam Pharmaceuticals as its ninth pharmaceutical partner. The partnership brings significant value to Illumina in multiple dimensions:

Alnylam's membership will fund sequencing of an additional 31,250 whole genomes, expanding the alliance's dataset to over 280,000 samples. This increased scale enhances the dataset's statistical power and commercial value to all members, directly benefiting Illumina as the technology provider.

The addition of an RNAi-focused company diversifies the alliance's therapeutic approaches. While previous members (AbbVie, Amgen, AstraZeneca, etc.) represent traditional drug modalities, Alnylam's gene-silencing technology creates new use cases for Illumina's sequencing data, potentially driving additional demand for their platforms.

The press release highlights that the AGD has already delivered tangible results - identifying novel therapeutic targets in autoimmune and neurodegenerative diseases - proving the commercial value of Illumina's genomic insights. The mention of expanding into proteomics suggests future revenue opportunities as Illumina adds multi-omic capabilities.

What's particularly valuable is how this partnership reinforces Illumina's ecosystem strategy. Rather than just selling sequencing instruments, they're positioning themselves at the center of a pharma R&D network, creating recurring revenue streams through their DRAGEN and Connected Analytics platforms that transform raw genomic data into actionable insights.

This partnership strengthens Illumina's competitive moat in the clinical genomics space by cementing their position as the infrastructure provider of choice for pharmaceutical target discovery.

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines

Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people

SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

"We welcome Alnylam to the AGD as our members continue to leverage data that fuels innovation in novel therapeutics to improve lives of patients everywhere," said Todd Christian, senior vice president of Services, Arrays and Genomic Access at Illumina. "Alnylam's decision to join the alliance speaks to the immense value of this resource that combines powerful scale and depth of sequencing with clinical data quality and diverse ancestral representation to advance the critical work of our biopharma partners."

Alnylam is the ninth member of the alliance, joining AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk. Alnylam's partnership will further strengthen the AGD clinical genomic database, enabling additional investment to sequence and analyze a new set of 31,250 whole-genomes to be added to the alliance's already groundbreaking 250,000 whole-genome cohort.

RNAi therapeutics function by "silencing" genes that cause or contribute to disease, working upstream of traditional treatment approaches. The AGD's dataset will provide a valuable resource for Alnylam scientists who hunt for new therapeutic targets.

"We are excited to join the Alliance for Genomic Discovery and contribute to the expansion of this important dataset, while simultaneously mining it for insights," said Paul Nioi, senior vice president of Research at Alnylam. "We rely on human genetics to guide us as we discover and develop RNAi therapeutics with the potential to change medicine. The AGD dataset will bolster our ability to identify therapeutic targets that are relevant to patients from many different backgrounds."

As of March 2025, the AGD completed a major milestone in developing the most comprehensive clinical genomic dataset to date. Making this cohort fully representative—by linking analyzed, ancestrally diverse genomic data with informative longitudinal clinical phenotyping—has been a core priority from the start, both to ensure that discoveries benefit all people, and to uncover insights that are often missed in more homogeneous datasets.

The alliance's pace of sequencing, rapid and secure data analysis, and generation of readily usable insights with DRAGEN™ and Illumina Connected Analytics have surpassed previous large-scale genomic efforts, which typically took three to five years to reach 100,000 sequenced genomes. Large-scale aggregation with DRAGEN Iterative gVCF Genotyper further enhances variant calling accuracy and consistency across diverse populations, enabling deeper insights into rare and complex genetic traits. 

The AGD dataset is already proving valuable to alliance members. Novel therapeutic targets, particularly in autoimmune and neurodegenerative diseases, have been identified or validated, with reports published or underway.

"We are thrilled that Alnylam has chosen to join the AGD and help us expand this unique dataset for all members," said Leeland Ekstrom, chief executive officer of NashBio. "Additional data scale, as well as other planned extensions, such as adding proteomics and extracting more clinical phenotypes from the unstructured parts of the linked electronic health records, will accelerate the pace and types of innovation possible with this resource."

This growth in the alliance's membership coincides with its plans to add multiomic layers to its dataset, which will facilitate faster and more efficient target discovery and therapy development. Illumina and NashBio are actively expanding the AGD network to continue building upon current successes, accelerating therapeutic discovery, and creating new standards for clinical R&D pace, cost efficiency, and efficacy. 

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

About NashBio

Nashville Biosciences LLC (NashBio), a wholly owned, for-profit subsidiary of Vanderbilt University Medical Center (VUMC), was created to make complex healthcare data easy to use for a wide range of life science research and development applications. Leveraging Vanderbilt University innovation, NashBio harnesses extensive real-world genomics and other longitudinal multi-modal datasets, along with powerful bioinformatics tools, to build and deliver a wide range of data products and services. NashBio works with clients in biotech, pharma, diagnostics, medical devices, and other life sciences domains to support their most critical use cases. We believe smarter data enables better outcomes for our clients and ultimately for patients. For more information, please visit NashBio.com, connect with us on LinkedIn or follow us on X at @NashvilleBio.

Contacts 

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-expanding-diverse-clinical-genomic-dataset-to-drive-precision-medicine-302560260.html

SOURCE Illumina, Inc.

FAQ

What is the significance of Alnylam joining the Alliance for Genomic Discovery (AGD)?

Alnylam's membership will strengthen the AGD by adding 31,250 new whole-genomes to the existing 250,000 whole-genome cohort, while allowing them to leverage the database for RNAi therapeutic target discovery.

How many members are now part of the Alliance for Genomic Discovery (AGD)?

The AGD now has nine members, including Alnylam, AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk.

What has the Alliance for Genomic Discovery (AGD) achieved as of March 2025?

AGD completed development of the most comprehensive clinical genomic dataset, linking diverse genomic data with longitudinal clinical phenotyping, and has identified novel therapeutic targets in autoimmune and neurodegenerative diseases.

How will Illumina's DRAGEN technology benefit the AGD partnership?

DRAGEN Iterative gVCF Genotyper enhances variant calling accuracy and consistency across diverse populations, enabling deeper insights into rare and complex genetic traits.

What are the future plans for the Alliance for Genomic Discovery dataset?

The AGD plans to add multiomic layers to its dataset and extract more clinical phenotypes from unstructured electronic health records to accelerate therapeutic discovery and development.
Illumina Inc

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Latest SEC Filings

ILMN Stock Data

15.84B
153.39M
0.19%
103.37%
4.69%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO